Tue, October 27, 2020
Mon, October 26, 2020
Fri, October 23, 2020
Thu, October 22, 2020
Wed, October 21, 2020
Tue, October 20, 2020
Mon, October 19, 2020

Evan Seigerman Maintained (BIIB) at Buy with Decreased Target to $350 on, Oct 22nd, 2020


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. th-decreased-target-to-350-on-oct-22nd-2020.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Evan Seigerman of Credit Suisse, Maintained "Biogen Inc." (BIIB) at Buy with Decreased Target from $359 to $350 on, Oct 22nd, 2020.

Evan has made no other calls on BIIB in the last 4 months.



There are 5 other peers that have a rating on BIIB. Out of the 5 peers that are also analyzing BIIB, 3 agree with Evan's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $265 on, Tuesday, October 20th, 2020
  • Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $277 on, Friday, September 18th, 2020
  • Carter Gould of "Barclays" Downgraded from Buy to Hold and Decreased Target to $280 on, Monday, June 22nd, 2020


These are the ratings of the 2 analyists that currently disagree with Evan


  • Geoff Meacham of "B of A Securities" Maintained at Sell with Decreased Target to $235 on, Thursday, October 15th, 2020
  • Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $342 on, Wednesday, August 19th, 2020

Publication Contributing Sources